Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

4(40.0%)

Phase 3

4(40.0%)

Phase 1

2(20.0%)

10Total

Phase 2(4)

Phase 3(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT00969878Phase 2Completed

Multisite Controlled Trial of Cocaine Vaccine

Role: collaborator

NCT00088166Phase 3Completed

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Role: lead

NCT01369121Phase 1Terminated

Tolerability Study of Xerecept® in Pediatric Patients

Role: lead

NCT00820092Phase 1Completed

Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers

Role: lead

NCT01790165Phase 2Completed

TDT 067 Open Label Multi-Dose Onychomycosis Study

Role: lead

NCT00226655Phase 3Completed

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Role: lead

NCT01145807Phase 3Unknown

TDT 067 Onychomycosis Study

Role: lead

NCT00633321Phase 2Completed

Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation

Role: lead

NCT00691522Phase 2Terminated

Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

Role: collaborator

NCT00226668Phase 3Withdrawn

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Role: lead

All 10 trials loaded